CarMax (KMX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +59.38%. A quarter ago, it was expected that this used car dealership chain would post earnings of $1.03 per share when it actually produced earnings of $0.64, delivering a surprise of -37.86%.Over the last four quarters, th ...

Core Insights - Samsara Inc. (IOT) shows a significant improvement in earnings outlook, making it an attractive investment option [1] - Analysts are optimistic about the company's earnings prospects, leading to rising earnings estimates [2] - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements [2][3] Current-Quarter Estimate Revisions - The expected earnings for the current quarter are $0.13 per share, reflecting an 18.2% year-over-year increase [7] - In the last 30 days, four estimates have been revised upward, with no negative revisions, resulting in a 40% increase in the Zacks Consensus Estimate [7] Current-Year Estimate Revisions - For the full year, the expected earnings are $0.50 per share, representing a 92.3% increase from the previous year [8] - Over the past month, five estimates have been revised upward, contributing to a 32.35% increase in the consensus estimate [9] Zacks Rank and Performance - Samsara Inc. has achieved a Zacks Rank 2 (Buy), indicating favorable estimate revisions and potential for outperformance [10] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [10] Bottom Line - Strong estimate revisions have led to a 9.9% increase in the stock price over the past four weeks, suggesting further upside potential [11]

Core Insights - Petco Health & Wellness reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of $0.01 per share, and showing an improvement from a loss of $0.02 per share a year ago, resulting in an earnings surprise of +400.00% [1] - The company generated revenues of $1.46 billion for the quarter ended October 2025, which was 0.44% below the Zacks Consensus Estimate and a decrease from $1.51 billion in the same quarter last year [2] - Petco's stock has underperformed, losing approximately 26.8% year-to-date compared to a 14% gain in the S&P 500 [3] Earnings Outlook - The future performance of Petco's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $1.53 billion, while for the current fiscal year, it is $0.12 on revenues of $5.98 billion [7] Industry Context - The Retail - Miscellaneous industry, to which Petco belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between stock movements and earnings estimate revisions, which could impact Petco's stock performance [5]

Core Insights - Energizer Holdings reported quarterly earnings of $1.05 per share, missing the Zacks Consensus Estimate of $1.12 per share, and down from $1.22 per share a year ago, representing an earnings surprise of -6.25% [1] - The company posted revenues of $832.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.21%, and up from $805.7 million year-over-year [2] - Energizer shares have declined approximately 31.6% year-to-date, contrasting with the S&P 500's gain of 13.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.72 on revenues of $762.57 million, and for the current fiscal year, it is $3.77 on revenues of $3.04 billion [7] - The estimate revisions trend for Energizer was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Consumer Products - Staples industry, to which Energizer belongs, is currently in the bottom 25% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Nerdy Inc. (NRDY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Investor Sentiment - The upgrade for Nerdy reflects an improvement in the company's underlying business, which is expected to drive stock appreciation as investors recognize this positive trend [5]. - Over the past three months, the Zacks Consensus Estimate for Nerdy has increased by 5.9%, indicating a positive revision in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates into five groups, with only the top 20% receiving a "Strong Buy" or "Buy" rating, suggesting superior potential for market-beating returns [9][10]. - Nerdy's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for price movement in the near term [10].

Core Insights - Xilio Therapeutics reported a quarterly loss of $0.03 per share, which aligns with the Zacks Consensus Estimate, showing improvement from a loss of $0.22 per share a year ago [1] - The company posted revenues of $19.07 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 28.51%, compared to revenues of $2.26 million in the same quarter last year [2] - Xilio Therapeutics shares have declined approximately 19% year-to-date, contrasting with a 16.5% gain in the S&P 500 [3] Financial Performance - The company has not surpassed consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, and for the current fiscal year, it is -$0.45 on revenues of $45.65 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Xilio Therapeutics is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 35% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Immatics, is expected to report a quarterly loss of $0.50 per share, with revenues projected to decline by 77.9% year-over-year [9]

Core Insights - Grindr Inc. (GRND) shows potential as a strong investment due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][8] - The trend of increasing earnings estimate revisions reflects growing analyst optimism, which is likely to positively impact the stock price [2][3] Current-Quarter Estimate Revisions - For the current quarter, Grindr is expected to earn $0.15 per share, representing a year-over-year increase of +66.7% [5] - Over the past 30 days, the Zacks Consensus Estimate for Grindr has risen by 15.39%, with one estimate moving higher and no negative revisions [5] Current-Year Estimate Revisions - The expected earnings for the full year are $0.53 per share, reflecting a substantial change of +488.9% from the previous year [6] - The trend for current-year estimates is also positive, with one estimate increasing and no negative revisions noted [6] Zacks Rank - Grindr currently holds a Zacks Rank 2 (Buy), indicating favorable estimate revisions that enhance its investment appeal [7] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [7] Bottom Line - The stock has gained 18.5% over the past four weeks, driven by solid estimate revisions, suggesting that it may be a good addition to investment portfolios [8]

Core Insights - nLight reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to a loss of $0.08 per share a year ago, representing an earnings surprise of +300.00% [1] - The company achieved revenues of $66.74 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.81% and showing an increase from $56.13 million year-over-year [2] - nLight's stock has increased approximately 200.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of nLight's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $58.31 million, while for the current fiscal year, it is $0.06 on revenues of $234.25 million [7] Industry Context - The Electronics - Semiconductors industry, to which nLight belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Insights - Treace Medical Concepts reported a quarterly loss of $0.26 per share, which was better than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of +7.14% [1] - The company achieved revenues of $50.21 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 1.27% and showing an increase from $45.09 million in the same quarter last year [2] - Treace Medical Concepts has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The company has reported a loss of $0.26 per share compared to a loss of $0.25 per share a year ago, indicating a slight deterioration year-over-year [1] - The stock has underperformed, losing about 16% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $77.57 million, while for the current fiscal year, it is projected at -$0.81 on revenues of $227.1 million [7] - The Zacks Rank for Treace Medical Concepts is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Treace Medical Concepts belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Treace Medical Concepts' stock performance [5]

Core Insights - Evergy Inc reported quarterly earnings of $2.03 per share, missing the Zacks Consensus Estimate of $2.14 per share, representing an earnings surprise of -5.14% [1] - The company posted revenues of $1.81 billion for the quarter ended September 2025, also missing the Zacks Consensus Estimate by 3.35% [2] - Evergy shares have increased by approximately 24.7% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Earnings Performance - Over the last four quarters, Evergy has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $1.27 billion, and for the current fiscal year, it is $4.01 on revenues of $5.95 billion [7] Market Outlook - The sustainability of Evergy's stock price movement will depend on management's commentary during the earnings call [3] - The Zacks Rank for Evergy is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Utility - Electric Power industry is currently in the top 23% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]